Your browser doesn't support javascript.
loading
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Halbach, Sebastian; Hu, Zehan; Gretzmeier, Christine; Ellermann, Julia; Wöhrle, Franziska U; Dengjel, Jörn; Brummer, Tilman.
Afiliação
  • Halbach S; Institute of Molecular Medicine and Cell Research (IMMZ), Faculty of Medicine, University of Freiburg, Freiburg, Germany. Sebastian.Halbach@sgbm.uni-freiburg.de.
  • Hu Z; Faculty of Biology, University of Freiburg, Freiburg, Germany. Sebastian.Halbach@sgbm.uni-freiburg.de.
  • Gretzmeier C; Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany. Sebastian.Halbach@sgbm.uni-freiburg.de.
  • Ellermann J; Freiburg Institute for Advanced Studies (FRIAS), and Center for Biological Systems Analysis (ZBSA), University of Freiburg, Freiburg, Germany. zehan.hu@hotmail.com.
  • Wöhrle FU; Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany. zehan.hu@hotmail.com.
  • Dengjel J; Freiburg Institute for Advanced Studies (FRIAS), and Center for Biological Systems Analysis (ZBSA), University of Freiburg, Freiburg, Germany. christine.gretzmeier@medizin.uni-freiburg.de.
  • Brummer T; Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany. christine.gretzmeier@medizin.uni-freiburg.de.
Cell Commun Signal ; 14: 6, 2016 Feb 24.
Article em En | MEDLINE | ID: mdl-26912052
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Leucemia Mielogênica Crônica BCR-ABL Positiva / Niacinamida / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Imidazóis / Indazóis Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Leucemia Mielogênica Crônica BCR-ABL Positiva / Niacinamida / Resistencia a Medicamentos Antineoplásicos / Inibidores de Proteínas Quinases / Imidazóis / Indazóis Idioma: En Ano de publicação: 2016 Tipo de documento: Article